279 related articles for article (PubMed ID: 28296827)
1. Vedolizumab Is Safe and Effective in Elderly Patients with Inflammatory Bowel Disease.
Navaneethan U; Edminister T; Zhu X; Kommaraju K; Glover S
Inflamm Bowel Dis; 2017 Apr; 23(4):E17. PubMed ID: 28296827
[No Abstract] [Full Text] [Related]
2. Vedolizumab is safe and effective in moderate-to-severe inflammatory bowel disease following liver transplantation.
Wright AP; Fontana RJ; Stidham RW
Liver Transpl; 2017 Jul; 23(7):968-971. PubMed ID: 28296011
[No Abstract] [Full Text] [Related]
3. Efficacy of Vedolizumab for Inflammatory Bowel Disease in the Setting of DiGeorge Syndrome.
Thau E; Moore HA; Stein P; Chen K
J Pediatr Gastroenterol Nutr; 2019 May; 68(5):e88. PubMed ID: 30889127
[No Abstract] [Full Text] [Related]
4. Blocking α4β7 Integrin Through Vedolizumab: Necessary but not Sufficient?
Dreesen E; Gils A
J Crohns Colitis; 2017 Aug; 11(8):903-904. PubMed ID: 28333273
[No Abstract] [Full Text] [Related]
5. Vedolizumab Concentrations in the Breast Milk of Nursing Mothers With Inflammatory Bowel Disease.
Julsgaard M; Kjeldsen J; Bibby BM; Brock B; Baumgart DC
Gastroenterology; 2018 Feb; 154(3):752-754.e1. PubMed ID: 28988916
[No Abstract] [Full Text] [Related]
6. Letter to editor: New onset/recurrence of inflammatory arthralgia/spondyloarthritis in patients treated with vedolizumab for intestinal bowel disease.
Tamanini S; Fredi M; Crisafulli F; Lazzaroni MG; Tincani A; Franceschini F
Clin Rheumatol; 2019 Feb; 38(2):609-610. PubMed ID: 30397839
[No Abstract] [Full Text] [Related]
7. Effects of Vedolizumab Therapy on Extraintestinal Manifestations in Inflammatory Bowel Disease.
Fleisher M; Marsal J; Lee SD; Frado LE; Parian A; Korelitz BI; Feagan BG
Dig Dis Sci; 2018 Apr; 63(4):825-833. PubMed ID: 29484571
[TBL] [Abstract][Full Text] [Related]
8. Effectiveness and Safety of Vedolizumab Induction Therapy for Patients With Inflammatory Bowel Disease.
Amiot A; Grimaud JC; Peyrin-Biroulet L; Filippi J; Pariente B; Roblin X; Buisson A; Stefanescu C; Trang-Poisson C; Altwegg R; Marteau P; Vaysse T; Bourrier A; Nancey S; Laharie D; Allez M; Savoye G; Moreau J; Gagniere C; Vuitton L; Viennot S; Aubourg A; Pelletier AL; Bouguen G; Abitbol V; Bouhnik Y; ;
Clin Gastroenterol Hepatol; 2016 Nov; 14(11):1593-1601.e2. PubMed ID: 26917043
[TBL] [Abstract][Full Text] [Related]
9. A real-world, long-term experience on effectiveness and safety of vedolizumab in adult patients with inflammatory bowel disease: The Cross Pennine study.
Lenti MV; Levison S; Eliadou E; Willert R; Kemp K; Carter A; Stansfield C; Assadsangabi A; Singh S; Crooks B; Tattersall S; Fairhurst F; Kenneth C; Subramanian S; Probert C; Storey D; Gregg B; Smith P; Liu E; Limdi JK; Johnston A; Hamlin PJ; Selinger CP
Dig Liver Dis; 2018 Dec; 50(12):1299-1304. PubMed ID: 30077465
[TBL] [Abstract][Full Text] [Related]
10. Designing biologic selectivity for inflammatory bowel disease--role of vedolizumab.
Krupka N; Baumgart DC
Drug Des Devel Ther; 2015; 9():147-54. PubMed ID: 25552903
[TBL] [Abstract][Full Text] [Related]
11. Safety of vedolizumab in liver transplant recipients: A systematic review.
Spadaccini M; Aghemo A; Caprioli F; Lleo A; Invernizzi F; Danese S; Donato MF
United European Gastroenterol J; 2019 Aug; 7(7):875-880. PubMed ID: 31428411
[TBL] [Abstract][Full Text] [Related]
12. Vedolizumab Effectiveness and Safety Over the First Year of Use in an IBD Clinical Practice.
Vivio EE; Kanuri N; Gilbertsen JJ; Monroe K; Dey N; Chen CH; Gutierrez AM; Ciorba MA
J Crohns Colitis; 2016 Apr; 10(4):402-9. PubMed ID: 26681763
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic Drug Monitoring With Ustekinumab and Vedolizumab in Inflammatory Bowel Disease.
Restellini S; Khanna R; Afif W
Inflamm Bowel Dis; 2018 Sep; 24(10):2165-2172. PubMed ID: 29788272
[TBL] [Abstract][Full Text] [Related]
14. Systemic Chemokine Levels with "Gut-Specific" Vedolizumab in Patients with Inflammatory Bowel Disease-A Pilot Study.
Zwicker S; Lira-Junior R; Höög C; Almer S; Boström EA
Int J Mol Sci; 2017 Aug; 18(8):. PubMed ID: 28829369
[TBL] [Abstract][Full Text] [Related]
15. Systematic review: the safety of vedolizumab for the treatment of inflammatory bowel disease.
Bye WA; Jairath V; Travis SPL
Aliment Pharmacol Ther; 2017 Jul; 46(1):3-15. PubMed ID: 28449273
[TBL] [Abstract][Full Text] [Related]
16. Dalbavancin, tedizolid phosphate, oritavancin diphosphate, and vedolizumab.
Hussar DA; Nguyen A
J Am Pharm Assoc (2003); 2014; 54(6):658-62. PubMed ID: 25379985
[No Abstract] [Full Text] [Related]
17. More evidence is needed on the additional efficacy of vedolizumab as a first-line biologic therapy for inflammatory bowel disease.
Kakiuchi T; Yoshiura M
Dig Liver Dis; 2023 Feb; 55(2):298-299. PubMed ID: 36411192
[No Abstract] [Full Text] [Related]
18. The role of ustekinumab and vedolizumab in management of extra intestinal manifestations in inflammatory bowel disease.
Katsanos KH; Fousekis FS; Armuzzi A
Dig Liver Dis; 2023 Feb; 55(2):149-150. PubMed ID: 36319583
[No Abstract] [Full Text] [Related]
19. Letter: tricky reactions to switch back from subcutaneous to intravenous vedolizumab in patients with inflammatory bowel disease.
Richard N; Vuitton L; Fumery M
Aliment Pharmacol Ther; 2023 Mar; 57(6):741-742. PubMed ID: 36821749
[No Abstract] [Full Text] [Related]
20. Lymphocyte homing antagonists in the treatment of inflammatory bowel diseases.
Saruta M; Papadakis KA
Gastroenterol Clin North Am; 2014 Sep; 43(3):581-601. PubMed ID: 25110260
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
